Patient-defined symptom burden and treatment utilization in a home-reported outcomes (HRO) study in sickle cell disease (SCD)

December 2023 at ASH

Authors/Institutions: Connie Zhang, MPH (Folia Health), Amanda Healey, MPH (Folia Health), Hiba Anwar, MPH (Folia Health), Nell Meosky Luo (Folia Health)

December 2023 at ASH

Authors/Institutions: Connie Zhang, MPH (Folia Health), Amanda Healey, MPH (Folia Health), Hiba Anwar, MPH (Folia Health), Nell Meosky Luo (Folia Health)

Enhancing the Understanding of Phenotypic Outcomes in Sickle Cell Disease (SCD) Through a Comparison Between Data Collected Through App-Based Home-Reported Outcomes (HROs) Versus Qualitative Methodologies

November 2023 at ISPOR Europe

Authors/Institutions: Connie Zhang, MPH (Folia Health), Amanda Healey, MPH (Folia Health), Hiba Anwar, MPH (Folia Health)

Patient-driven study design and implementation in an app-based research program measuring home-reported outcomes in sickle cell disease (SCD)

October 2023 at SCDAA

Authors/Institutions: Connie Zhang, MPH (Folia Health), Amanda Healey, MPH (Folia Health), Hiba Anwar, MPH (Folia Health), Nell Meosky Luo, BS (Folia Health)

Leveraging patient-generated data beyond clinical trials: a meta-analysis review of the HRO framework in cystic fibrosis (1048)

October 2023 at ISOQOL

Authors/Institutions: Connie Zhang, MPH (Folia Health), Nell Meosky Luo, BS (Folia Health), Paula Mello Ferber, BA (Folia Health)

Identifying potential flare events in rare disease by applying a threshold-based analysis approach to home-reported outcomes

October 2023 at ISOQOL

Authors/Institutions: Hiba Anwar, MPH (Folia Health), Liz Rowe (Folia Health), Amanda Healey, MPH (Folia Health) Connie Zhang, MPH (Folia Health), Paula Mello Ferber, BA (Folia Health), Nell Meosky Luo, BS (Folia Health)

Canopy Series: Designing a Community-Driven Research Initiative with Accessible Data Insights

October 2023 at NORD Summit

Authors/Institutions: Connie Zhang, MPH (Folia Health), Isabella Chao, BA (Folia Health), Hiba Anwar, MPH (Folia Health), Nell Meosky Luo, BS (Folia Health)

Home Reported Outcomes (HERO-2) in People with CF Taking Elexacaftor/tezacaftor/ivacaftor: Self-Reported Changes in Use of Chronic Daily Therapies at Enrollment

June 2023 at ECFS

Authors/Institutions: Clement Ren, MD MBA (University of Pennsylvania), Kevin Psoter, PhD, MPA (Johns Hopkins University), Kathryn Sabadosa, MPH (CF Foundation), Nell Meosky Luo, BS (Folia Health), Connie Zhang, MPH (Folia Health), Lisa Bendy (CF Foundation), Cynthia Brown, MD (Indiana University)

Preliminary Observations of Treatment and Symptom Reporting in the Home-Reported Outcomes in CF Study (HERO-2)

June 2023 at ECFS

Authors/Institutions: Cynthia Brown, MD (Indiana University), Nell Meosky Luo, BS (Folia Health), Connie Zhang, MPH (Folia Health), Kathryn Sabadosa, MPH (CF Foundation), Clement Ren, MD MBA (University of Pennsylvania)

Patient-Driven RWD Outside of the Clinic: Demystifying the Capture of Home Reported Outcomes in Rare Diseases

May 2023 at ISPOR

Authors/Institutions: Connie Zhang, MPH; Nell Meosky Luo
Folia Health

Novel Data Capture Method for the Identification of Potential Flare Events in Chronic Diseases Via Patient Self-Tracking: Insights from Use Case in Sickle Cell Disease (SCD)

May 2023 at ISPOR

Authors/Institutions: Nell Meosky Luo; Hiba Anwar, MPH; Amanda Healey, MPH; Jacob Kean MEd, PhD; Connie Zhang, MPH;
Folia Health; University of Utah

Home-Reported Outcomes in CF: Learning from our CF Heroes

November 2022, Clement Ren MD, MBA (Children’s Hospital of Philadelphia)

As presented at the North American Cystic Fibrosis Conference (NACFC) in 2022

Insights from Patients and Caregivers living with Rare Disorders: Value of Patient-Generated Health Data Beyond the Walls of Clinical Research

October 2022

As presented at the NORD Breakthrough Summit in 2022

Authors/Institutions: Hiba Anwar, MPH; Paula Mello Ferber; Nell Meosky Luo; Connie Zhang, MPH; Elizabeth Rowe, OTR/L, MOT
Folia Health

Assessing the application of a novel hybrid natural language processing-qualitative analysis framework to understand caregiver-reported impact during DCCR therapy in Prader-Willi Syndrome

September 2022

As presented at the FPWR Symposium in 2022

Authors/Institutions: Hiba Anwar MPH, Folia Health; Adam Pittman, Folia Health; Nell Meosky Luo, Folia Health; Kristen Yen, Soleno Therapeutics; Anish Bhatnagar, Soleno Therapeutics

Application of a novel hybrid natural language processing-qualitative analytic method to characterize efficacy of DCCR in Prader-Willi Syndrome

July 2022
As presented at the 11th International Prader Willi Syndrome Organization Conference in 2022

Implementation and preliminary experiences of the HERO-2 real-world research study in patients with cystic fibrosis

June 2022

As presented at the 45th European Cystic Fibrosis Society Conference in 2022

Authors/Institutions: Linh Do, Cystic Fibrosis Foundation; Cynthia Brown, MD, Indiana University; Nell Meosky Luo, Folia Health; Connie Zhang, MPH, Folia Health; Gunnar Esiason, MBA, MPH; Jacqui Sjoberg; Kevin Psoter, PhD, MPA, Johns Hopkins University; Kathryn Sabadosa, MPH, Cystic Fibrosis Foundation; Clement Ren, MD, MBA, University of Pennsylvania

Application of a semi-automated framework to characterize individual experiences with DCCR in Prader-Willi syndrome (PWS)

April 2021

Press release

As presented at the Pediatric Academic Societies 2021 Meeting

(search “DCCR” for full presentation content)

Authors/Institutions: Adam Pittman, Folia Health; Nell Meosky Luo, Folia Health; Mindy Leffler, Casimir Trials; Kristina Davis, Casimir Trials; Sonya Elder, Casimir Trials; Megan Hefner, Casimir Trials; Patricia C. Hirano, Soleno Therapeutics; Kristen Yen, Soleno Therapeutics; Anish Bhatnagar, Soleno Therapeutics

Background: PWS is a rare genetic disorder characterized by hyperphagia, behavioral challenges, intellectual disability and body composition differences. DCCR tablets are in development to treat PWS and have shown evidence of efficacy in a Phase 3 study. Due to heterogeneity in the population and the impact of environment on behavior, no single tool exists to reliably measure meaningful change in behaviors resulting from pharmacological treatment.

Objective: Using transcripts of caregiver interviews conducted during the open-label extension phase of the DCCR Phase 3 program, an inventory of PWS behaviors was created to capture a more complete view of participant outcomes. This framework was then applied to characterize responses to DCCR. We hypothesized that each participant experiences a subset of potential PWS behaviors and that behavioral changes with DCCR can be detected within this subset for each individual.

Design/Methods: Qualitative semi-structured interviews of caregivers were conducted by Casimir. Folia applied a natural language processing (topic modelling, sentiment analysis) and qualitative analysis (framework & content analyses) to develop a PWS behavioral corpus and outcome inventory, then to assign a binary “incidence” and “change” score for each behavior in each participant and test reproducibility.

Results: In 48 interviews, 39 behavioral outcomes in 7 outcome domains were identified. The average participant experienced 22±5.9 behaviors; most frequent domains: Food-seeking Behaviors (100%), Mealtime Behaviors (98%), Daily Life Behaviors (98%). Most participants (83%) reported positive change in ≥1 behavioral outcome on DCCR, while 71% and 48% showed improvement in ≥ 25% or ≥50% behaviors, respectively. A minority of participants (23%) experienced a negative behavior change; 6% had >1. Positive changes were found in all 7 domains.

Conclusion(s): In complex diseases like PWS, it is important for clinical research to capture variation in individual patient experiences, to form a more complete view of therapeutic impact. Using such a framework, participants in the DCCR Phase 3 program experienced several positive behavioral outcomes associated with treatment. In future PWS studies, it is desirable to account for individual variation by enabling measurement of different behaviors-of-interest of study participants, with population analysis focused on comparison of change at the domain level.

HomE Reported Outcomes (HERO) Study: A Real-World Research Pilot of Virtual Enrollment & Home-Tracking in CF

Methods for Monitoring Pulmonary Health in Cystic Fibrosis Patients in a Remote-First Care Environment - A Survey

October 2020

As published in Pediatric Pulmonology, Volume 55,  Issue S2, The 34th Annual North American Cystic Fibrosis Conference

Methods for monitoring pulmonary health in cystic fibrosis patients in a remote-first care environment - a Survey

Published: May 21, 2020

Abstract: Utilizing an App-Based System to Conduct a Real-World Evidence Study of Treatment Use and Outcomes.

Published: October 2019

As presented at NACFC 2019

Authors: Luo, N.M.; Fink, A.; Sabadosa, K.

Background: As CFTR modulators are used by increasing numbers of CF patients, our ability to track impact on health and well-being, as well as to understand the most-effective combination of treatments for each individual patient, is limited without systematically collecting patient- and family-reported data. Folia is a cloud-based platform that enables the capture of home-reported outcomes (HROs) by patients and family caregivers (PFC). Folia has been previously piloted in CF programs in Maine Medical Center, Dell Medical School, and University of Vermont Medical Center. Users select the data elements they choose to collect, including symptom presence, severity, characteristics; follow-through with treatments; biometrics; problematic behavior frequency; and wellness indicators. Folia utilizes multiple-choice questions to simplify data capture. Data can be reported to a clinical team in a PDF at or before an appointment.

Objectives: (1) Determine optimal strategies for recruiting study participants; (2) Assess consistency of data entry throughout study; (3) Measure PFC satisfaction with app-based study participation; (4) Understand to what extent current users of CFTR modulators have made other changes to their treatment regimens.

Methods: We will use three arms for study recruitment: 1) current users of Folia; 2) clinic-based enrollment - individuals will be provided information about Folia and this study from their CF care center; 3) ambassador-based enrollment - PFC will share information about Folia and the study on social media. Once individuals are enrolled in Folia and onsent to participate in the study, they will be asked to complete questions regarding use of daily CF treatments, including: airway clearance; CFTR modulators; dornase alfa; hypertonic saline; and inhaled antibiotics. Study follow-up will be six weeks, and data will be linked to the CF Foundation Patient Registry. At the end of the study, each participant will complete a survey to assess their satisfaction with the app, the feasibility of conducting a long-term study using Folia, and whether having this tracked data impacted their behavior and care.

Results: Enrollment metrics will be 1) percentage of current Folia users who agree to provide their data for this research project; 2) percentage of individuals who receive information about Folia from their clinic who enroll in the study; 3) number of users who enroll in Folia from an ambassador. Among individuals enrolled, we will stratify by enrollment type and examine 1) the distribution of the number of days they enter data into Folia; 2) the percentage of people with variability in treatment regimens during the follow-up period; 3) key reasons reported for varying treatment regimens; and 4) satisfaction with Folia

Conclusions: Technology provides an opportunity to enrich our research with data elements provided real-time by individuals with CF and their caregivers. This study will help us understand the feasibility of using Folia to conduct a real-world research study of treatment withdrawal in the era of highly effective CFTR modulators.

Can mHealth Technology help to mitigate the effects of the COVID-19 pandemic?

Published in the Institute of Electrical and Electronics Engineers (IEEE) Open Journal of Engineering

August 13, 2020